Q-omics provides the consensus-scored OR7E100P profile across patient tissues and cancer cell-line models. OR7E100P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OR7E100P is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, OR7E100P RNA expression shows 8,842 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, LUAD, and GBM as cancer lineages where OR7E100P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E100P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E100P survival associations across molecular data types. OR7E100P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E100P RNA expression–survival associations across cancer types. High OR7E100P expression shows unfavorable associations in THCA, KICH, KIRC and ACC, but favorable associations in UCEC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for OR7E100P RNA expression.
This table summarizes OR7E100P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E100P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E100P shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP and LIHC. The LUAD box plot shows higher OR7E100P RNA expression in normal versus tumor tissue (log2 FC = −0.192, t-test p < 0.001).
This table shows molecular features associated with OR7E100P in patient tissues and cancer cell lines. In patient samples, OR7E100P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
